+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 70Years
All Genders
ID07246096

Pilot Study of Anti-CD19BCMA Universal CAR-T Cell Therapy for Adults With Relapsed or Resistant Autoimmune Diseases

Led by Changhai Hospital · Updated on 2026-02-25

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of anti-CD19BCMA U CAR T cells in patients with relapsed or refractory autoimmune diseases. This early phase 1, single-arm, open-label pilot study plans to enroll 60 patients to understand how this treatment works in conditions such as systemic lupus erythematosus, systemic sclerosis, primary Sjgren syndrome, rheumatoid arthritis, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Participants will receive a dose-escalation treatment with anti-CD19BCMA CAR T cells called KN3601. Before the CAR T cell infusion, patients will be given Fludarabine and Cyclophosphamide on days -5, -4, and -3. The study will monitor the effects of a single-dose injection of these CAR T cells over a 52-week period following infusion. During the study, participants will be closely observed for dose-limiting toxicities and treatment-emergent adverse events up to 52 weeks after infusion. Researchers will also measure overall response rates, disease control rates, B cell depletion and recovery. Patients will undergo regular assessments and follow-ups throughout the study period to track safety and treatment impact, with the total observation lasting up to one year after treatment.

CONDITIONS

Brief Title

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Research Team

D

Dongbao Zhao

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here